NCT04159688 is a EARLY_PHASE1 clinical trial of Alcohol in Alcohol Drinking, sponsored by Yale University.

Who is sponsoring NCT04159688?

NCT04159688 is sponsored by Yale University.

What drugs are being tested in NCT04159688?

Interventions in NCT04159688: Alcohol.

What condition does NCT04159688 study?

NCT04159688 studies Alcohol Drinking.

Is NCT04159688 still recruiting?

NCT04159688 is currently completed. Last updated 9 October 2024.

Are results published for NCT04159688?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-10-09 · How we verify

NCT04159688

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Imaging Glutamate Release From Alcohol

Completed EARLY_PHASE1 Results posted Last updated 9 October 2024

What this trial tests

EARLY_PHASE1 trial testing Alcohol in Alcohol Drinking in 8 participants. Completed in 30 June 2022.

Timeline

1 March 2020

Primary endpoint
30 June 2022

30 June 2022

Quick facts

Lead sponsor	Yale University
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	8
Start date	1 March 2020
Primary completion	30 June 2022
Estimated completion	30 June 2022
Sites	1 location across United States

Drugs / interventions tested

Alcohol — full drug profile →

Conditions studied

Alcohol Drinking — all drugs for Alcohol Drinking →

Sponsor

Yale University

Who can join

Adults 21 to 55, any sex, with Alcohol Drinking. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Alcohol-induced Change in Receptor Availability Primary · Baseline and within 2 hours of challenge

The percent change in receptor availability will be measured from the PET data. Since this project is for basic science it is not known whether positive values are better or worse outcome.

Group	Value	95% CI
Alcohol Challenge	-9.1	-11.2 – -6.6

Sponsor's own description

The goal of this research project is to determine the sensitivity of PET radioligands specific for targets in the glutamate system to an alcohol challenge.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Alcohol

Trials testing the same drug.

NCT07282405 — Validation of Alcohol Level Identification Using DRIVESC · NA · completed
NCT06576674 — Satiety and Alcohol Challenge · NA · completed
NCT06579521 — Real-world Experiences of Alcohol and Cognitions Over Time · NA · completed
NCT06326684 — Suvorexant and Alcohol · EARLY_PHASE1 · recruiting
NCT05929677 — Impulsivity Domains and Subjective Response · EARLY_PHASE1 · recruiting

Other recruiting trials for Alcohol Drinking

Currently open trials in the same condition.

NCT07415707 — The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in N · NA · recruiting
NCT06815237 — Effects of Ketone Supplement and Alcohol on Brain Metabolism · Phase 2, PHASE3 · recruiting
NCT06994962 — Multi-Component Breath Alcohol Intervention Phase 3 · NA · recruiting
NCT05363878 — Development of a Culturally Grounded, Trauma-Informed Alcohol Intervention With a Reserve-Dwelling First Nation Group · NA · recruiting
NCT06309134 — The Healthy Families Bright Futures Program · NA · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04159688 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 9 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04159688.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing